Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Balovaptan for malignant cerebral edema risk after acute ischemic stroke
2021-002076-39Phase 2Terminated
- Sponsor
- Roche
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ischemic stroke comparing Balovaptan with Placebo (2 arms). Primary endpoint: Amount of midline shift. Started Jan 2022; status: terminated.
02
Drugs
balovaptan
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on 2021-002076-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002076-39.